homepage-top-section

Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered

The partnership brings together a high-titre glutamine synthetase (GS) knockout (−/−) Chinese hamster ovary (CHO) cell line solution, free from additional intellectual property costs, aiming to streamline the

These facilities will integrate advanced manufacturing technologies and AI for supporting production of the company’s obesity and next-generation neuroscience medications. Construction is scheduled to commence in spring 2026,

This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes and facilitate the delivery of scientifically validated, partner-ready therapeutic candidates. It will combine Syngene’s

The collaboration will combine Mayo Clinic’s Platform architecture and clinical-genomic datasets with MSD’s virtual cell technologies to improve target identification, drive early development decisions, and enhance disease understanding.

The placement was led by existing investor BVF Partners and joined by entities such as Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional

This approval provides a new option for long-term disease control in patients, with twice-yearly maintenance dosing after two initial loading doses. gMG is a rare, chronic, B-cell-mediated autoimmune

The therapies are approved as second or third line treatment for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express programmed death-ligand 1 (PD-L1)

The companies plan to jointly develop at least two research and development (R&D) programmes using Insilico Medicine’s AI platform alongside CMS’ expertise in clinical development. Under the agreement,